ChemicalBook Chinese Germany Japanese Korean

怀化元研达生物技术有限责任公司 Company Information
Company Name:    Huaihua Yuanyanda Biotechnology Co., Ltd
Tel:    -
Email:    18711085600@163.com
Nationality:    China
WebSite:   
Product List:    4590
36 37 38 39 40 41 42 43 44 45 46
Product List
Clopidogrel EP Impurity A 144457-28-3
Troxagliptin impuritiesX 1938080-44-4
Clopidogrel Impurities8 782477-51-4
LCZ696 impurities506-07 2216746-87-9
(S)-Clopidogrel N-Oxide 1319197-71-1
alogliptin impurities7 1618644-32-8
Afatinib Impurity11 2044709-72-8
Dabigatran Impurity 21 1643392-59-9
Dabigatran etexilate impurity6 1643377-48-3
LCZ696 impuritiesA 761373-05-1
Olmesartan Medoxomil Impurity10 144690-04-0
Azilsartan medoxomil impurityC 1397836-49-5
Erlotinib Impurity M 1346601-52-2
alogliptin impurities4 865759-10-0
Gefitinib Impurity 5 246512-44-7
alogliptin impurities1 1134529-25-1
Azilsartan medoxomil Impurity H 1499167-72-4
Afatinib Impurity10 2223677-60-7
Linezolid Impurity11 868405-66-7
Cetirizine EP Impurity C 83881-59-8
Gefitinib Impurity 6 1608115-59-8
LCZ697 impuritiesB 766480-48-2
Afatinib Impurity6 179552-74-0
Dabigatran etexilate impurity14 429658-95-7
Sorafenib impurities14 862875-16-9
Azilsartan medoxomil impurity5 1696392-12-7
Linezolid Impurity 21 368891-70-7
Gefitinib Impurity14 847949-56-8
LCZ696 impurities1 2376611-98-0
Troxagliptin impuritiesY 1938080-42-2
Clopidogrel Impurities4 1195954-07-4
Olmesartan Medoxomil Impurity14 1048948-15-7
Linezolid Impurity14 168828-89-5
Erlotinib Impurity D 1145671-52-8
Oxcarbazepine EP Impurity H 4698-11-7
Cetirizine Impurity2 1232460-31-9
Olmesartan Medoxomil EP Impurity C 879562-26-2
Cetirizine EP ImpurityD 346451-15-8
Erlotinib Impurity7 183320-04-9
Linezolid Impurity4 2180621-71-8
Dabigatran etexilate impurity4 2225986-95-6
Olmesartan Medoxomil Impurity19 144689-24-7
Azilsartan medoxomil Impurity J 1403474-78-1
Levocetirizine Impurity 5 1391052-52-0
Linezolid dimer 908143-04-4
Sorafenib impurities7 2206827-12-3
Troxagliptin impurities1 2087874-94-8
Azilsartan medoxomil Impurity B 1696392-11-6
Clopidogrel Impurities1 1346231-36-4
Linezolid Related Compound A 168828-84-0
alogliptin impurities8 1638544-64-5
Linezolid Impurity2 2512211-93-5
Cetirizine Impurity1 164726-80-1
Erlotinib Impurity E 183320-15-2
Azilsartan medoxomil impurity1 147403-52-9
(R)-Cetirizine EP Impurity A 300543-56-0
Erlotinib Impurity4 183365-34-6
Linezolid ImpurityC 168828-90-8
Olmesartan Medoxomil Impurity7 144690-33-5
Dabigatran Impurity 22 658078-29-6
Cetirizine EP Impurity F 83881-53-2
Cetirizine EP Impurity B DiHCl 1000690-91-4
Oxcarbazepine EP Impurity F 28721-08-6
Clopidogrel EP Impurity E(S) 444728-13-6
Olmesartan Medoxomil Impurity13 1347262-29-6
Linezolid Impurity3 556801-12-8
Dabigatran Impurity U 1408238-41-4
Azilsartan medoxomil impurity3 856414-36-3
Gefitinib Impurity15 199327-61-2
alogliptin impurities6 865758-98-1
Afatinib Impurity2 2348580-72-1
Cetirizine Amide Dihydrochloride 200707-85-3
Oxcarbazepine Impurity 4 33948-20-8
Dabigatran Impurity 19 2225986-94-5
Gefitinib Impurity I 1502829-45-9
Olmesartan Medoxomil EP Impurity B 849206-43-5
LCZ696 impurities575-11 1038924-71-8
Dabigatran Impurity 23 211915-07-0
Linezolid Hydrochloride Impurity D 1391068-25-9
Erlotinib Impurity1 236750-62-2
Dabigatran Methyl Ester Impurity 771459-37-1
Afatinib Impurity5 1259015-90-1
Linezolid Impurity15 1798014-14-8
LCZ696 impuritiesC 149709-63-7
Olmesartan Medoxomil Impurity8 144689-93-0
Linezolid N-Oxide 189038-36-6
Dabigatran etexilate impurity11 1408238-37-8
LCZ696 impurities3 1012341-56-8
Desethyl Dabigatran Etexilate 212321-78-3
Olmesartan Medoxomil Impurity11 2101308-73-8
Troxagliptin impurities4 20787874-91-5
Sorafenib impurities10 1012058-78-4
Oxcarbazepine EP Impurity D 19579-83-0
Afatinib Impurity7 2475094-95-0
Clopidogrel EP Impurity B HCl 1396607-35-4
Afatinib Impurity1 2223677-58-3
Erlotinib Impurity A 183322-21-6
LCZ696 impuritiesE 1012341-52-4
Clopidogrel EP Impurity E 90055-68-8
Dabigatran etexilate impurity10 1408238-36-7
36 37 38 39 40 41 42 43 44 45 46
Copyright 2007©  ChemicalBook. All rights reserved.